These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36893375)

  • 1. Design and Implementation of a Nationwide Population-Based Longitudinal Survey of SARS-CoV-2 Infection in Spain: The ENE-COVID Study.
    Pastor-Barriuso R; Pérez-Gómez B; Oteo-Iglesias J; Hernán MA; Pérez-Olmeda M; Fernández-de-Larrea N; Molina M; Fernández-García A; Martín M; Cruz I; Sanmartín JL; León-Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R; Pollán M
    Am J Public Health; 2023 May; 113(5):525-532. PubMed ID: 36893375
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
    Pollán M; Pérez-Gómez B; Pastor-Barriuso R; Oteo J; Hernán MA; Pérez-Olmeda M; Sanmartín JL; Fernández-García A; Cruz I; Fernández de Larrea N; Molina M; Rodríguez-Cabrera F; Martín M; Merino-Amador P; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R;
    Lancet; 2020 Aug; 396(10250):535-544. PubMed ID: 32645347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Infection During the First and Second Pandemic Waves in Spain: the ENE-COVID Study.
    Pérez-Gómez B; Pastor-Barriuso R; Fernández-de-Larrea N; Hernán MA; Pérez-Olmeda M; Oteo-Iglesias J; Fernández-Navarro P; Fernández-García A; Martín M; Cruz I; Sanmartín JL; León-Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R; Pollán M
    Am J Public Health; 2023 May; 113(5):533-544. PubMed ID: 36893370
    [No Abstract]   [Full Text] [Related]  

  • 4. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study.
    Pastor-Barriuso R; Pérez-Gómez B; Hernán MA; Pérez-Olmeda M; Yotti R; Oteo-Iglesias J; Sanmartín JL; León-Gómez I; Fernández-García A; Fernández-Navarro P; Cruz I; Martín M; Delgado-Sanz C; Fernández de Larrea N; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Larrauri A; Pollán M;
    BMJ; 2020 Nov; 371():m4509. PubMed ID: 33246972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Authors' response: Occupation and SARS-CoV-2 infection risk among workers during the first pandemic wave in Germany: potential for bias.
    Reuter M; Rigó M; Formazin M; Liebers F; Latza U; Castell S; Jöckel KH; Greiser KH; Michels KB; Krause G; Albrecht S; Öztürk I; Kuss O; Berger K; Lampl BMJ; Leitzmann M; Zeeb H; Starke KR; Schipf S; Meinke-Franze C; Ahrens W; Seidler A; Klee B; Pischon T; Andreas Deckert AD; Schmidt B; Mikolajczyk R; Karch A; Bohn B; Brenner H; Holleczek B; Dragano N
    Scand J Work Environ Health; 2022 Sep; 48(7):588-590. PubMed ID: 36153787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the nationwide seroprevalence ENE-COVID study in Spain.
    Pérez-Olmeda M; Saugar JM; Fernández-García A; Pérez-Gómez B; Pollán M; Avellón A; Pastor-Barriuso R; Fernández-de Larrea N; Martín M; Cruz I; Sanmartín JL; Fedele G; Paniagua JL; Muñoz-Montalvo JF; Blanco F; Yotti R; Oteo-Iglesias J;
    J Clin Virol; 2022 Apr; 149():105130. PubMed ID: 35305377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Oct; 22(1):694. PubMed ID: 34635140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain.
    Varona JF; Madurga R; Peñalver F; Abarca E; Almirall C; Cruz M; Ramos E; Castellano Vázquez JM
    Int J Epidemiol; 2021 May; 50(2):400-409. PubMed ID: 33434269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys.
    Hallal PC; Hartwig FP; Horta BL; Silveira MF; Struchiner CJ; Vidaletti LP; Neumann NA; Pellanda LC; Dellagostin OA; Burattini MN; Victora GD; Menezes AMB; Barros FC; Barros AJD; Victora CG
    Lancet Glob Health; 2020 Nov; 8(11):e1390-e1398. PubMed ID: 32979314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys.
    Angulo FJ; Finelli L; Swerdlow DL
    JAMA Netw Open; 2021 Jan; 4(1):e2033706. PubMed ID: 33399860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
    García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM
    Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey.
    Mutevedzi PC; Kawonga M; Kwatra G; Moultrie A; Baillie V; Mabena N; Mathibe MN; Rafuma MM; Maposa I; Abbott G; Hugo J; Ikalafeng B; Adelekan T; Lukhele M; Madhi SA
    Int J Epidemiol; 2022 May; 51(2):404-417. PubMed ID: 34718591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the Impact of the COVID-19 Pandemic in Spain: Large-Scale, Online, Self-Reported Population Survey.
    Oliver N; Barber X; Roomp K; Roomp K
    J Med Internet Res; 2020 Sep; 22(9):e21319. PubMed ID: 32870159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Fox T; Geppert J; Dinnes J; Scandrett K; Bigio J; Sulis G; Hettiarachchi D; Mathangasinghe Y; Weeratunga P; Wickramasinghe D; Bergman H; Buckley BS; Probyn K; Sguassero Y; Davenport C; Cunningham J; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Struyf T; Van den Bruel A; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Deeks JJ;
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013652. PubMed ID: 36394900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study.
    Pallett SJC; Rayment M; Patel A; Fitzgerald-Smith SAM; Denny SJ; Charani E; Mai AL; Gilmour KC; Hatcher J; Scott C; Randell P; Mughal N; Jones R; Moore LSP; Davies GW
    Lancet Respir Med; 2020 Sep; 8(9):885-894. PubMed ID: 32717210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study.
    Álvarez-Antonio C; Meza-Sánchez G; Calampa C; Casanova W; Carey C; Alava F; Rodríguez-Ferrucci H; Quispe AM
    Lancet Glob Health; 2021 Jul; 9(7):e925-e931. PubMed ID: 34022148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data.
    Cabezón-Gutiérrez L; Custodio-Cabello S; Palka-Kotlowska M; Oliveros-Acebes E; García-Navarro MJ; Khosravi-Shahi P
    Cancer Treat Rev; 2020 Nov; 90():102102. PubMed ID: 32947121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.